Membrane-interactive lipids as experimental anticancer drugs.

por Berdel, W. E.
Publicado 1991

Loss of expression of HDAC-recruiting methyl-CpG-binding domain proteins in human cancer

por Müller-Tidow, C, Kügler, K, Diederichs, S, Klümpen, S, Möller, M, Vogt, U, Metzger, R, Schneider, P M, Berdel, W E, Serve, H
Publicado 2001

MATE1 regulates cellular uptake and sensitivity to imatinib in CML patients

por Harrach, S, Schmidt-Lauber, C, Pap, T, Pavenstädt, H, Schlatter, E, Schmidt, E, Berdel, W E, Schulze, U, Edemir, B, Jeromin, S, Haferlach, T, Ciarimboli, G, Bertrand, J
Publicado 2016

MN1–Fli1 oncofusion transforms murine hematopoietic progenitor cells into acute megakaryoblastic leukemia cells

por Wenge, D V, Felipe-Fumero, E, Angenendt, L, Schliemann, C, Schmidt, E, Schmidt, L H, Thiede, C, Ehninger, G, Berdel, W E, Arteaga, M-F, Mikesch, J-H
Publicado 2015

Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity

por Herzog, J., von Klot-Heydenfeldt, F., Jabar, S., Ranft, A., Rossig, C., Dirksen, U., Van den Brande, J., D'Incalci, M., von Luettichau, I., Grohar, P. J., Berdel, W. E., Burdach, St.
Publicado 2016

Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry

por Kaifie, A., Kirschner, M., Wolf, D., Maintz, C., Hänel, M., Gattermann, N., Gökkurt, E., Platzbecker, U., Hollburg, W., Göthert, J. R., Parmentier, S., Lang, F., Hansen, R., Isfort, S., Schmitt, K., Jost, E., Serve, H., Ehninger, G., Berdel, W. E., Brümmendorf, T. H., Koschmieder, S.
Publicado 2016

Karyotype complexity and prognosis in acute myeloid leukemia

por Stölzel, F, Mohr, B, Kramer, M, Oelschlägel, U, Bochtler, T, Berdel, W E, Kaufmann, M, Baldus, C D, Schäfer-Eckart, K, Stuhlmann, R, Einsele, H, Krause, S W, Serve, H, Hänel, M, Herbst, R, Neubauer, A, Sohlbach, K, Mayer, J, Middeke, J M, Platzbecker, U, Schaich, M, Krämer, A, Röllig, C, Schetelig, J, Bornhäuser, M, Ehninger, G
Publicado 2016

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

por Hehlmann, R, Lauseker, M, Saußele, S, Pfirrmann, M, Krause, S, Kolb, H J, Neubauer, A, Hossfeld, D K, Nerl, C, Gratwohl, A, Baerlocher, G M, Heim, D, Brümmendorf, T H, Fabarius, A, Haferlach, C, Schlegelberger, B, Müller, M C, Jeromin, S, Proetel, U, Kohlbrenner, K, Voskanyan, A, Rinaldetti, S, Seifarth, W, Spieß, B, Balleisen, L, Goebeler, M C, Hänel, M, Ho, A, Dengler, J, Falge, C, Kanz, L, Kremers, S, Burchert, A, Kneba, M, Stegelmann, F, Köhne, C A, Lindemann, H W, Waller, C F, Pfreundschuh, M, Spiekermann, K, Berdel, W E, Müller, L, Edinger, M, Mayer, J, Beelen, D W, Bentz, M, Link, H, Hertenstein, B, Fuchs, R, Wernli, M, Schlegel, F, Schlag, R, de Wit, M, Trümper, L, Hebart, H, Hahn, M, Thomalla, J, Scheid, C, Schafhausen, P, Verbeek, W, Eckart, M J, Gassmann, W, Pezzutto, A, Schenk, M, Brossart, P, Geer, T, Bildat, S, Schäfer, E, Hochhaus, A, Hasford, J
Publicado 2017